Most recent data suggest that, by differential expression of ASCL1, NEUROD1 and POU2F3, or low expression of all three transcription factors with an inflamed genetic signature, four SCLC subtypes exist, with the inflamed subtype (SCLC-I) being the most sensitive to immunotherapy [10]. Here, POU2F3 is linked to small cell lung carcinoma.